TherapeuticsMD (TXMD) Interest Coverage Ratio (2010 - 2025)
TherapeuticsMD's (TXMD) quarterly Interest Coverage Ratio came in at 287.33 in Q3 2025, up 23.99% on a YoY basis from 231.75 in Q3 2024, and up 17.31% quarter-over-quarter from 347.5 in Q2 2025.
Powered by 
Analysis
TherapeuticsMD (TXMD) Interest Coverage Ratio (2010 - 2025) Analysis & Trends
TherapeuticsMD (TXMD) has reported Interest Coverage Ratio for 12 consecutive years, with 287.33 the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, Interest Coverage Ratio rose 23.99% year-over-year to 287.33; the trailing twelve-month figure through Sep 2025 stood at 349.0 (down 281.62% YoY), and the FY2021 full-year result was 2.42, up 55.58% from the prior year.
- Interest Coverage Ratio grew to 287.33 in Q3 2025 per TXMD's latest filing, from 347.5 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 1.24 in Q1 2022 and bottomed at 640.5 in Q1 2025.
- Historically, Interest Coverage Ratio has averaged 186.67 across 5 years, with a median of 54.93 in 2023.
- The sharpest annual moves came in 2021 and 2023: Interest Coverage Ratio soared 64.8% in 2021, then sank 4200.62% in 2023.
- Over 5 years, Interest Coverage Ratio stood at 4.67 in 2021, then soared by 73.45% to 1.24 in 2022, then sank by 7047.55% to 88.65 in 2023, then slumped by 326.4% to 378.0 in 2024, then rose by 23.99% to 287.33 in 2025.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 287.33, 347.5, and 640.5 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 25.41 |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | 10.28 |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | - |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 3.65 |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | -21.24 |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 8.18 |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -287.33 |
| Jun 30, 2025 | -347.50 |
| Mar 31, 2025 | -640.50 |
| Sep 30, 2024 | -378.00 |
| Jun 30, 2024 | -557.80 |
| Sep 30, 2023 | -88.65 |
| Jun 30, 2023 | -54.93 |
| Mar 31, 2023 | -53.34 |
| Mar 31, 2022 | -1.24 |
| Dec 31, 2021 | -4.67 |
| Sep 30, 2021 | -5.31 |
| Jun 30, 2021 | -4.63 |
| Mar 31, 2021 | -2.86 |
| Dec 31, 2020 | -4.55 |
| Sep 30, 2020 | -3.25 |
| Jun 30, 2020 | -6.41 |
| Mar 31, 2020 | -8.13 |
| Dec 31, 2019 | -7.84 |
| Sep 30, 2019 | -4.84 |
| Jun 30, 2019 | -10.34 |